Puma Biotechnology (PBYI) Q2 FY26 earnings call

Puma Biotechnology delivered a strong second quarter, driven by robust NERLYNX sales and increased demand, leading to an upward revision in full-year revenue and net income guidance. The company also achieved a significant financial milestone by becoming debt-free. While new prescriptions saw a slight decline, the focus remains on commercial execution and advancing the alisertib clinical pipeline, with plans to initiate Phase III trials in the future.